Clinical/Translational Cancer Immunotherapy

Section Edited by Douglas G. McNeel, MD, PhD; Claudia Palena, PhD; and Jeffrey S. Weber, MD, PhD

First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations; tumor microenvironment; combination therapies; and cell therapies.

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, Mateus Crespo, Ana Ferreira, Bora Gurel, Toby Prout, Malaka Ameratunga, Maxime Chénard-Poirier, Andra Curcean, Claudia Bertan, Chloe Baker, Susana Miranda, Nahal Masrour, Wentin Chen, Rita Pereira, Ines Figueiredo, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Ruth Riisnaes, Mona Parmar, Alison Turner, Suzanne Carreira, Christina Yap, Robert Brown, Nina Tunariu, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom

10.1136/jitc-2022-004495

June 18, 2022